Project title
DOVE試驗 (Dostarlimab 單獨使用或與 Bevacizumab 聯合治療，對比非鉑類化療在復發性婦科亮細胞癌中的三臂隨機 II 期研究)的轉譯醫學研究
Internal ID
NSTC114-2314-B002-065
Principal Investigator
Start Date
August 1, 2025
End Date
July 31, 2026
Organizations
Partner Organizations
Translational Research of the Dove Trial: a Three-Arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma = DOVE試驗 (Dostarlimab 單獨使用或與 Bevacizumab 聯合治療，對比非鉑類化療在復發性婦科亮細胞癌中的三臂隨機 II 期研究)的轉譯醫學研究
Keywords
Tumor immune microenvironment
DOVE clinical trial
Clear cell carcinoma
Description
The expected impacts of this project are as follows: Social Impact: Enhancing treatment outcomes and improving the quality of life for patients with gynecological clear cell carcinoma while reducing the disease burden and promoting the well-being of patients and their families. Economic Impact: Lowering unnecessary treatment costs and healthcare expenditures associated with side effects through precision medicine, leading to more efficient utilization of healthcare resources. Academic Development: Offering new research insights and scientific evidence in immunotherapy for gynecological clear cell carcinoma, advancing translational medicine, and providing a foundation for international academic collaboration. This project seeks to drive the development of more personalized therapeutic strategies, offering significant contributions to cancer immunotherapy and serving as a valuable reference and practical advancement.